Literature DB >> 19414781

The adaptor molecule MyD88 directly promotes CD8 T cell responses to vaccinia virus.

Yuan Zhao1, Carl De Trez, Rachel Flynn, Carl F Ware, Michael Croft, Shahram Salek-Ardakani.   

Abstract

Vaccinia virus (VACV) elicits a robust CD8 T cell response that plays an important role in host resistance. To date, there is little information on the molecules that are essential to generate large pools of VACV-specific effector CD8 T cells. In this study, we show that the adaptor molecule MyD88 is critical for the magnitude of primary CD8 T cell responses to both dominant and subdominant VACV epitopes. MyD88(-/-) mice exhibit profound reduction in CD8 T cell expansion and antiviral cytokine production. Surprisingly, the defect was not due to impaired APC function, as MyD88(-/-) dendritic cells matured normally and were able to promote strong CD8 T cell priming following VACV infection. Rather, adoptive transfer experiments demonstrated that intrinsic MyD88-dependent pathways in CD8 T cells were critical. MyD88-deficient CD8 T cells failed to accumulate in wild-type hosts and poor expansion of MyD88-deficient VACV-specific CD8 T cells resulted after virus infection. In contrast, no defect was evident in the absence of TRIF, TLR2, TLR4, TLR9, and IL-1R. Together, our results highlight an important role for MyD88 in initial antiviral CD8 T cell responses and suggest that targeting this pathway may be useful in promoting and sustaining anti-VACV immunity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19414781      PMCID: PMC2712123          DOI: 10.4049/jimmunol.0803682

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  49 in total

1.  A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling.

Authors:  A Bowie; E Kiss-Toth; J A Symons; G L Smith; S K Dower; L A O'Neill
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

2.  A consensus epitope prediction approach identifies the breadth of murine T(CD8+)-cell responses to vaccinia virus.

Authors:  Magdalini Moutaftsi; Bjoern Peters; Valerie Pasquetto; David C Tscharke; John Sidney; Huynh-Hoa Bui; Howard Grey; Alessandro Sette
Journal:  Nat Biotechnol       Date:  2006-06-11       Impact factor: 54.908

3.  Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity.

Authors:  Nicole Asprodites; Liqin Zheng; Degui Geng; Cruz Velasco-Gonzalez; Luis Sanchez-Perez; Eduardo Davila
Journal:  FASEB J       Date:  2008-06-27       Impact factor: 5.191

4.  MyD88 plays a critical T cell-intrinsic role in supporting CD8 T cell expansion during acute lymphocytic choriomeningitis virus infection.

Authors:  Adeeb H Rahman; Weiguo Cui; David F Larosa; Devon K Taylor; Jidong Zhang; Daniel R Goldstein; E John Wherry; Susan M Kaech; Laurence A Turka
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

5.  Importance of myeloid differentiation factor 88 in innate and acquired immune protection against genital herpes infection in mice.

Authors:  Sara Tengvall; Ali M Harandi
Journal:  J Reprod Immunol       Date:  2007-10-22       Impact factor: 4.054

6.  A critical role for direct TLR2-MyD88 signaling in CD8 T-cell clonal expansion and memory formation following vaccinia viral infection.

Authors:  Michael Quigley; Jennifer Martinez; Xiaopei Huang; Yiping Yang
Journal:  Blood       Date:  2008-10-23       Impact factor: 22.113

7.  OX40 drives protective vaccinia virus-specific CD8 T cells.

Authors:  Shahram Salek-Ardakani; Magdalini Moutaftsi; Shane Crotty; Alessandro Sette; Michael Croft
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

8.  Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines.

Authors:  Joseph D Miller; Robbert G van der Most; Rama S Akondy; John T Glidewell; Sophia Albott; David Masopust; Kaja Murali-Krishna; Patryce L Mahar; Srilatha Edupuganti; Susan Lalor; Stephanie Germon; Carlos Del Rio; Mark J Mulligan; Silvija I Staprans; John D Altman; Mark B Feinberg; Rafi Ahmed
Journal:  Immunity       Date:  2008-05-08       Impact factor: 31.745

9.  Protective effect of Toll-like receptor 4 in pulmonary vaccinia infection.

Authors:  Martha A Hutchens; Kathryn E Luker; Joanne Sonstein; Gabriel Núñez; Jeffrey L Curtis; Gary D Luker
Journal:  PLoS Pathog       Date:  2008-09-19       Impact factor: 6.823

10.  Robust intrapulmonary CD8 T cell responses and protection with an attenuated N1L deleted vaccinia virus.

Authors:  Anuja Mathew; Joel O'Bryan; William Marshall; Girish J Kotwal; Masanori Terajima; Sharone Green; Alan L Rothman; Francis A Ennis
Journal:  PLoS One       Date:  2008-10-02       Impact factor: 3.240

View more
  43 in total

1.  Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccine.

Authors:  Basav N Hangalapura; Dinja Oosterhoff; Tarun Gupta; Jan de Groot; Pepijn G J T B Wijnands; Victor W van Beusechem; Joke den Haan; Thomas Tüting; Alfons J M van den Eertwegh; David T Curiel; Rik J Scheper; Tanja D de Gruijl
Journal:  Vaccine       Date:  2011-01-25       Impact factor: 3.641

2.  The TNFR family members OX40 and CD27 link viral virulence to protective T cell vaccines in mice.

Authors:  Shahram Salek-Ardakani; Rachel Flynn; Ramon Arens; Hideo Yagita; Geoffrey L Smith; Jannie Borst; Stephen P Schoenberger; Michael Croft
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

3.  Influence of different delivery modes on the clinical characteristics of Chlamydia trachomatis pneumonia.

Authors:  Jiejing Xu; Lili Yu; Baidi Fu; Deyu Zhao; Feng Liu
Journal:  Eur J Pediatr       Date:  2018-05-31       Impact factor: 3.183

4.  Inhibition of IRAK1/4 sensitizes T cell acute lymphoblastic leukemia to chemotherapies.

Authors:  Zhaoyang Li; Kenisha Younger; Ronald Gartenhaus; Ann Mary Joseph; Fang Hu; Maria R Baer; Patrick Brown; Eduardo Davila
Journal:  J Clin Invest       Date:  2015-02-02       Impact factor: 14.808

5.  MyD88-dependent immunity to a natural model of vaccinia virus infection does not involve Toll-like receptor 2.

Authors:  Michael L Davies; Janet J Sei; Nicholas A Siciliano; Ren-Huan Xu; Felicia Roscoe; Luis J Sigal; Laurence C Eisenlohr; Christopher C Norbury
Journal:  J Virol       Date:  2014-01-08       Impact factor: 5.103

6.  Quantitative and qualitative features of heterologous virus-vector-induced antigen-specific CD8+ T cells against Trypanosoma cruzi infection.

Authors:  Eiji Takayama; Takeshi Ono; Elena Carnero; Saori Umemoto; Yoko Yamaguchi; Atsuhiro Kanayama; Takemi Oguma; Yasuhiro Takashima; Takushi Tadakuma; Adolfo García-Sastre; Yasushi Miyahira
Journal:  Int J Parasitol       Date:  2010-07-08       Impact factor: 3.981

7.  CD8 marks a subpopulation of lung-derived dendritic cells with differential responsiveness to viral infection and toll-like receptor stimulation.

Authors:  Nicole M Beauchamp; Rama D Yammani; Martha A Alexander-Miller
Journal:  J Virol       Date:  2012-07-18       Impact factor: 5.103

8.  HVEM Imprints Memory Potential on Effector CD8 T Cells Required for Protective Mucosal Immunity.

Authors:  Pritesh Desai; Georges Abboud; Jessica Stanfield; Paul G Thomas; Jianxun Song; Carl F Ware; Michael Croft; Shahram Salek-Ardakani
Journal:  J Immunol       Date:  2017-09-01       Impact factor: 5.422

9.  Boosting functional avidity of CD8+ T cells by vaccinia virus vaccination depends on intrinsic T-cell MyD88 expression but not the inflammatory milieu.

Authors:  Zhidong Hu; Jing Wang; Yanmin Wan; Lingyan Zhu; Xiaonan Ren; Sugan Qiu; Yanqin Ren; Songhua Yuan; Xiangqing Ding; Jian Chen; Chenli Qiu; Jun Sun; Xiaoyan Zhang; Jim Xiang; Chao Qiu; Jianqing Xu
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

10.  The RIG-I-like receptor LGP2 controls CD8(+) T cell survival and fitness.

Authors:  Mehul S Suthar; Hilario J Ramos; Margaret M Brassil; Jason Netland; Craig P Chappell; Gabriele Blahnik; Aimee McMillan; Michael S Diamond; Edward A Clark; Michael J Bevan; Michael Gale
Journal:  Immunity       Date:  2012-07-26       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.